In a landmark case involving the intersection of competition and investment law, the US Federal Trade Commission (FTC) has filed a lawsuit against U.S. Anesthesia Partners Inc. and its private equity founder. The FTC alleges that the firm implemented an anticompetitive scheme to amass significant market power via a series of roll-up acquisitions.
A report from JD Supra traces the origin of this ongoing legal dispute back to a series of acquisitions, or ‘roll-ups’, which the agency concludes resulted in reduced competition, thereby hampering the free-market economy. The FTC’s complaint marks a significant development in US antitrust law, especially given the increasing oversight of private equity firms and their potential to diminish market competitiveness through acquisition strategies.
The complaint filed by the FTC alleges that U.S. Anesthesia Partners collaborated with its private equity founder in order to dominate the market unlawfully. Through orchestrated roll-up acquisitions, the firm effectively decreased the marketplace’s competitiveness, thus creating a market environment wherein they could dictate pricing and contract terms.
The case has ramifications for private equity firms and portfolio companies, shedding light on the potential antitrust risks associated with roll-up strategies. Legal professionals specialising in antitrust law and private equity investments will closely follow this case. It is anticipated to set new precedents in how American antitrust law applies to private equity businesses and their roll-up acquisition strategies.